Settlements have been reached in a class action lawsuit regarding the price that consumers and third-party payors paid for Provigil® and generic versions of Provigil® (Modafinil).

You may be able to recover money if you are a consumer or a third-party payor who paid for or reimbursed all or part of the cost of Provigil® or Modafinil in certain states during the period from June 24, 2006 through August 8, 2019.

The lawsuit asserts that Defendants Cephalon, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc. (collectively, “Cephalon”), Mylan Pharmaceuticals Inc. and Mylan, Inc. (formerly known as Mylan Laboratories, Inc.) (collectively, “Mylan”), and Sun Pharmaceuticals Industries, Ltd., as successor in interest to Ranbaxy Laboratories, Ltd. and Ranbaxy Pharmaceuticals, Inc., (collectively “Ranbaxy”) violated state antitrust and consumer protection laws relating to the sale of the prescription pharmaceutical Provigil. All Defendants have denied any wrongdoing.

A $48,000,000 Settlement has been reached between the End-Payor Class Plaintiffs (consumers and third-party payors) and the Cephalon Defendants, a $14,377,600 Settlement with the Mylan Defendants, and a $3,500,000 Settlement with the Ranbaxy Defendants. The three Settlements total $65,877,600.

SRK, as co-lead counsel, has begin the process of sending notice to class members.  Consumers and health plans will have until December 6, 2019 to exclude themselves from the settlements, and until January 15, 2020 to object or file a claim.  The Court will hold a final approval hearing on February 26, 2020 in Philadelphia.

The settlement administrator has created a web site – click here.

Or you may contact SRK’s lead attorney, John Macoretta at 215-496-0300 or